On July 29th 2018, the second CSCO - Hansoh Tumor Forum & Academic Conference upon the 10th Anniversary of the Launch of Pulaile (Pemetrexed Disodium for Injection) was held in Shanghai. 10 academic authorities from CSCO (Chinese Society of Clinical Oncology) made professional and impressive oncology and pharmacology speeches at the meeting, and more than 300 oncologists from all over the country shared in this academic feast. 

To encourage the clinical research and exploration of oncology in China, Hansoh Pharma and CSCO Foundation jointly established CSCO Hansoh Oncology Fund at the meeting. The Fund will focus on oncology scholarship and application development, so as to benefit domestic cancer patients. 

Cancer treatment is a key drug research field of Hansoh Pharma. The Company has made huge R&D investments over nearly 20 years to tackle tumor pathogenesis and develop effective and safe treatment medicines. Its key products have been included in the "national major projects for development of important new drugs". Several high-quality anti-tumor drugs, including Zefei (Gemcitabine Hydrochloride for Injection), Pulaile (Pemetrexed Disodium for Injection), Gainuo (Vinorelbine Tartrate Injection), Xinwei (Imatinib Mesylate Tablets), Xinmei (Decitabine for Injection), have been launched and have helped millions of cancer patients improve their quality of life. 

Now, Hansoh Pharma has also brought good news to overseas patients with its anti-tumor drugs: several anti-tumor preparations have entered the mainstream markets of the USA and Europe. Zefei and Gainuo passed FDA certification in 2012, and Pulaile passed PMDA certification in 2016. Hansoh Pharma took the lead in the industry to develop international preparations and was granted the title of “A Pioneer for International Preparations among Chinese Pharmaceutical Enterprises”.